Eliana Clark - Mar 1, 2023 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role: EVP, Chief Technical Officer
Signature: James Basta, attorney-in-fact
Stock symbol: NTLA
Transactions as of: Mar 1, 2023
Transactions value $: $0
Form type: 4
Date filed: 3/3/2023, 04:12 PM
Previous filing: Jan 6, 2023
Next filing: Jun 22, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NTLA	Common Stock	Award	$0	+24.5K	+169.55%	$0.00	39K	Mar 1, 2023	Direct	F1
transaction	NTLA	Common Stock	Award	$0	+6.13K	+15.72%	$0.00	45.1K	Mar 1, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NTLA	Stock Option (right to buy)	Award	$0	+34.7K		$0.00	34.7K	Mar 1, 2023	Common Stock	34.7K	$40.75	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2	This option was granted on March 1, 2023 with respect to shares of Common Stock, with 33% vesting on January 1, 2024 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.